light signal that allows the high speed and dynamics of signal generation and measurement. It provides the rst test result in 18 minutes and has a maximum throughput of 86 tests per hour. The system can develop both competitive and sandwich-format electrochemiluminescent assays.The Elecsys 2010 system is a fully automated immunoassay analyser that can work in batch, random, or stat modes. The automated process consists of the aspiration of the sample, reagent and microparticles, a rst incubation at 378 C, additional reagent pipetting, a second incubation at 378 C, reaction mixture aspiration, and measurement. The analyser also includes a workstation for system programming and can be interfaced to various laboratory computers.
Elecsys 2010 CYFRA 21-1 assayNo pre-analytical preparation of reagents is required for the Elecsys 2101 CYFRA 21-1 assay (cat. no. 1820966). In a rst incubation of nine minutes, 20.m L of sample, a biotinylated monoclonal cytokeratin 19-speci c antibody, and a monoclonal cytokeratin 19-speci c antibody labelled with a ruthenium complex [a tris(2,29 -bipyridyl)ruthenium (II) complex] react to form a sandwich complex. After the addition of streptavidin-coated microparticles, there is a second incubation for nine minutes, and the complex becomes bound to the solid phase via the interaction of biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with a phosphate-tripropylamine buffer (pH 6.8; Procell ® , BM). Application of a voltage to the electrode then induces chemiluminescent emission, which is measured by a photomultiplier.We agree with Dr Kuropkat regarding the role of CYFRA 21-1 for follow-up in patients with head and neck squamous cell carcinoma (HNSCC). The data including our study have shown that CYFRA 21-1 is a good marker for monitoring therapeutic effect, follow-up and prognostic value in patients with HNSCC.2-5 Furthermore, many studies have shown that CYFRA 21-1 is useful for diagnosis of HNSCC.5-10 We also believe that CYFRA 21-1 is an adjunct for the diagnosis of HNSCC. The CYFRA 21-1 ECLIA provides a useful tool for the surveillance of patients suffering from carcinoma of the head and neck.We have an attention on the dif culty of identication of the appropriate cut-off level. Different methods have different recommended value. Certainly, the different cut-off value ought to be established according to the statistic analysis of an ample study of different tumours.We support Dr Kuropkat's opinion that the survival rate depends on the tumour site. Our study also identi ed this idea, although other explanations are possible. Moreover, we have been investigating the survival rate of our cases studied according to different tumour sites.